BiotechTube
Rafarm

Rafarm

Athens, Europe - Other· Est.
rafarmgroup.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Rafarm is a well-established, privately-held Greek pharmaceutical manufacturer with a nearly 50-year history, now pivoting to a hybrid business model combining generic drug development, advanced CDMO services, and out-licensing. Its core technological expertise lies in complex sterile formulations, particularly ophthalmics and injectables, supported by ongoing investments in modern production lines. The company aims to leverage its scientific expertise and agile operations to accelerate drug development for partners and expand its international footprint through dossier licensing and product supply.

Ophthalmology

Technology Platform

Integrated expertise in the development and aseptic manufacturing of complex sterile dosage forms, with a specialized focus on ophthalmic and injectable pharmaceuticals.

Opportunities

Growing global demand for complex generics and sterile CDMO services provides a significant expansion opportunity.
Rafarm's specialized expertise in ophthalmics and injectables allows it to target high-value, high-barrier market segments with less competition than simple generics.
Out-licensing of regulatory dossiers offers a capital-efficient path to global reach without establishing a direct commercial footprint in every country.

Risk Factors

Intense competition from larger global generics manufacturers and CDMOs with greater financial and commercial resources.
High regulatory risk associated with sterile manufacturing; any significant compliance failure could severely impact operations.
Dependency on retaining specialized scientific talent in a competitive market.

Competitive Landscape

Rafarm competes in the complex generics and sterile CDMO space against large multinational generic companies (e.g., Viatris, Hikma, Teva) and specialized CDMOs (e.g., Recipharm, CordenPharma, Ajinomoto Bio-Pharma). Its competitive differentiation is based on agility, specialized expertise in ophthalmics, and a hybrid business model combining proprietary development with client services from a European base with EMA standards.

More companies in Small Molecule Drugs →More companies in Europe - Other →